Vaccine Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Streptococcal Infection
Peptidase Vaccine Clears Group B Streptococci
April 11th, 2001
by N.R. Saltmarsh, staff medical writer - The use of streptococcal C5a peptidase (SCPB) in a vaccine against group B streptococci (GBS) confers protection from not only GBS but possibly all streptococcal serotypes, according to a report in Infection and Immunity. SCPB is a surface protein expressed by all streptococcal serotypes tested. Qi Cheng and colleagues at the University of Minnesota proposed its use as a possible carrier protein that could itself confer immunity. "In this study, we examined the potential of antibody directed against SCPB from a serotype II strain to enhance the capacity of mouse bone marrow macrophages (from primary...
Source: Vaccine Weekly (2001-04-11)
|
